Terms: = Germ cell tumor AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
44 results:
1. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
Lv D; Zhong C; Dixit D; Yang K; Wu Q; Godugu B; Prager BC; Zhao G; Wang X; Xie Q; Bao S; He C; Heiland DH; Rosenfeld MG; Rich JN
Mol Cell; 2023 Dec; 83(23):4334-4351.e7. PubMed ID: 37979586
[TBL] [Abstract] [Full Text] [Related]
2. KPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function.
Wang LH; Wei S; Yuan Y; Zhong MJ; Wang J; Yan ZX; Zhou K; Luo T; Liang L; Bian XW
Autophagy; 2024 Feb; 20(2):295-310. PubMed ID: 37712615
[TBL] [Abstract] [Full Text] [Related]
3. Effect of selinexor on lipogenesis in virus-positive Merkel cell carcinoma cell lines.
Landes JR; Bartley BR; Moore SA; He Q; Simonette R; Rady PL; Doan HQ; Tyring SK
Clin Exp Dermatol; 2023 Jul; 48(8):903-908. PubMed ID: 37191210
[TBL] [Abstract] [Full Text] [Related]
4. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract] [Full Text] [Related]
5. Combining selinexor with alisertib to target the p53 pathway in neuroblastoma.
Nguyen R; Wang H; Sun M; Lee DG; Peng J; Thiele CJ
Neoplasia; 2022 Apr; 26():100776. PubMed ID: 35217309
[TBL] [Abstract] [Full Text] [Related]
6. SAPCD2 promotes neuroblastoma progression by altering the subcellular distribution of E2F7.
Zhang ZM; Cao HB; Li ZH; Zhuo R; Tao YF; Li XL; Li G; Liao XM; Fang F; Xie Y; Wu D; Wang HR; Wang JW; Chen YL; Yu JJ; Jia SQ; Yang RD; Guo XY; Yang Y; Feng CX; Xu YY; Qian GH; Pan J
Cell Death Dis; 2022 Feb; 13(2):174. PubMed ID: 35197448
[TBL] [Abstract] [Full Text] [Related]
7. Selinexor is a novel inhibitor of DNA damage response in Merkel cell carcinoma.
Moore SA; Narayanan D; Simonette RA; Bartley BR; Doan HQ; Rady PL; Tyring SK
Clin Exp Dermatol; 2022 Jul; 47(7):1354-1357. PubMed ID: 35120268
[TBL] [Abstract] [Full Text] [Related]
8. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
[TBL] [Abstract] [Full Text] [Related]
9. Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma.
Degorre C; Tofilon P; Camphausen K; Mathen P
Radiat Oncol; 2021 Sep; 16(1):191. PubMed ID: 34583727
[TBL] [Abstract] [Full Text] [Related]
10. xpo1/crm1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.
Pan L; Cheng C; Duan P; Chen K; Wu Y; Wu Z
J Exp Clin Cancer Res; 2021 Aug; 40(1):255. PubMed ID: 34384466
[TBL] [Abstract] [Full Text] [Related]
11. Chemoproteomic Profiling of Covalent xpo1 Inhibitors to Assess Target Engagement and Selectivity.
Martin JG; Ward JA; Feyertag F; Zhang L; Couvertier S; Guckian K; Huber KVM; Johnson DS
Chembiochem; 2021 Jun; 22(12):2116-2123. PubMed ID: 33887086
[TBL] [Abstract] [Full Text] [Related]
12. Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide crm1-Inhibitor.
Sui M; Xiong M; Li Y; Zhou Q; Shen X; Jia D; Gou M; Sun Q
Int J Nanomedicine; 2021; 16():2833-2847. PubMed ID: 33883894
[TBL] [Abstract] [Full Text] [Related]
13. Subcellular Distribution of p53 by the p53-Responsive lncRNA
Mitra S; Muralidharan SV; Di Marco M; Juvvuna PK; Kosalai ST; Reischl S; Jachimowicz D; Subhash S; Raimondi I; Kurian L; Huarte M; Kogner P; Fischer M; Johnsen JI; Mondal T; Kanduri C
Cancer Res; 2021 Mar; 81(6):1457-1471. PubMed ID: 33372039
[TBL] [Abstract] [Full Text] [Related]
14. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract] [Full Text] [Related]
15. YAP promotes the proliferation of neuroblastoma cells through decreasing the nuclear location of p27
Shen X; Xu X; Xie C; Liu H; Yang D; Zhang J; Wu Q; Feng W; Wang L; Du L; Xuan L; Meng C; Zhang H; Wang W; Wang Y; Xie T; Huang Z
Cell Prolif; 2020 Feb; 53(2):e12734. PubMed ID: 31863533
[TBL] [Abstract] [Full Text] [Related]
16. The sodium pump α1 subunit regulates bufalin sensitivity of human glioblastoma cells through the p53 signaling pathway.
Lan YL; Zou YJ; Lou JC; Xing JS; Wang X; Zou S; Ma BB; Ding Y; Zhang B
Cell Biol Toxicol; 2019 Dec; 35(6):521-539. PubMed ID: 30739221
[TBL] [Abstract] [Full Text] [Related]
17. Integration of protein interaction and gene co-expression information for identification of melanoma candidate genes.
Wu K; Wang W; Ye Y; Huang J; Zhou Y; Zhang Y; Zhang X; Wu W
Melanoma Res; 2019 Apr; 29(2):126-133. PubMed ID: 30451788
[TBL] [Abstract] [Full Text] [Related]
18. Dual Inhibition of Bcl-2/Bcl-xL and xpo1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract] [Full Text] [Related]
19. A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group.
Margol AS; Yeo KK; Xia C; Onar A; Robison NJ; Freyer DR; Dhall G
J Neurooncol; 2018 Dec; 140(3):575-582. PubMed ID: 30173409
[TBL] [Abstract] [Full Text] [Related]
20. Detection of circulating tumour cell clusters in human glioblastoma.
Krol I; Castro-Giner F; Maurer M; Gkountela S; Szczerba BM; Scherrer R; Coleman N; Carreira S; Bachmann F; Anderson S; Engelhardt M; Lane H; Evans TRJ; Plummer R; Kristeleit R; Lopez J; Aceto N
Br J Cancer; 2018 Aug; 119(4):487-491. PubMed ID: 30065256
[TBL] [Abstract] [Full Text] [Related]
[Next]
